One-year clinical results with actarit—a preliminary report

Abstract

The effectiveness and safety of 1-year treatment with actarit were evaluated in patients with rheumatoid arthritis. Treatment was continued for 1 year or longer in 18 of the 34 patients. Early improvement in morning stiffness, grip strength, joint score and the Lansbury’s index were observed. Improvement in 1-h eythrocyte sedimentation rate was observed at the 12-month assessment. IgG was decreased at the 12-month assessment. Obvious improvement in C-reactive protein was not seen through the trial. No abnormal findings were noted in routine blood tests. Adverse reactions of special note were skin eruption in one patient and digestive symptom in one patient. However, no serious adverse reactions were observed.     

医教协同培养儿童药物临床研究人才的探索与实践

目的 在药学专业型研究生培养中探索儿童药物临床研究人才的培养模式。方法 分析儿童药物临床研究者应具备的素质，构建系统化、多层次的医教协同培养机制，以应用为导向优化课程体系，以儿科药物治疗需求为驱动引导学位论文选题，加强培养过程监管。通过促进研究生角色和观念转换，进行儿童药物临床研究技术培训，促进成果转化，强化研究生儿童药物临床研究能力培养。结果 初步建成了基于医教协同理念的儿童药物临床研究人才培养模式，培养的研究生符合社会与行业需求。结论 构建医教协同培养机制是培养儿童药物临床研究人才的重要路径。     

Fatal metabolic stroke in a child with propionic acidemia 11 years post liver transplant

Propionic acidemia is a rare autosomal recessive inborn error of metabolism caused by a deficiency of propionyl CoA carboxylase which often manifests with frequent metabolic decompensations and risk of neurological injury. Outcomes with medical therapy remain suboptimal. Liver transplantation has been shown to be a therapeutic option for patients and results in a milder phenotype of the disease and partial correction of the enzyme defect. Liver transplantation has been increasingly reported over the last decade and experience in managing these patients is improving. Long-term outcomes are generally good; however, the risk of complications still exists despite transplantation. We report a child who presented with a fatal metabolic stroke 11 years post liver transplant without any biochemical evidence of decompensation. We highlight the need to closely monitor these patients lifelong despite liver transplantation and maintain multidisciplinary working between hepatology and metabolic clinicians.     

New drugs for the treatment of coronary artery syndromes: otamixaban and ticagrelor

Acute coronary syndromes are a major cause of mortality and morbidity. The objective of this evaluation is to review the clinical trials of two new drugs being developed for the treatment of acute coronary syndromes. The first drug is the anticoagulant otamixaban, and the trial compared otamixaban with unfractionated heparin and eptifibatide in acute coronary syndromes. The second drug is the antiplatelet ticagrelor, and the trial compared ticagrelor with clopidogrel in acute coronary syndromes. In the SEPIA-ACS1 TIMI 42 trial, the primary efficacy endpoint occurred in 6.2% of subjects treated with unfractionated heparin and eptifibatide, and to a significantly lesser extent with otamixaban. In the PLATO trial, the primary efficacy endpoint had occurred less in the ticagrelor group (9.8%) than in the clopidogrel group (11.7%) at 12 months. Two new drugs for acute coronary syndromes, otamixaban and ticagrelor, have recently been shown to have benefits in subjects undergoing percutaneous interventions compared to the present standard regimens for this condition.     

伏九贴敷治疗儿童反复咳喘100例临床观察

目的：观察“伏九贴敷”治疗儿童反复咳喘的临床疗效。方法：采用随机对照的方法，将200例反复咳喘患几分成观察组（贴敷组）和对照组（非贴敷组）各100例。观察组给予伏九贴敷治疗，2年为1个疗程。结果：“伏九贴敷”在平喘及消除肺部哮鸣音等方面，显效84例，有效13例，无效3例，总有效率97％，两组有显著性意义。结论：“伏九贴敷”用于治疗咳喘疗效确切，值得临床进一步推广。     

X-连锁低血磷性佝偻病的治疗现状及展望

X-连锁低血磷性佝偻病(XLH)属于遗传性代谢性骨病,发病机制复杂,在临床上较为罕见,其主要临床表现为骨骼畸形及身材矮小,致残率高,因而针对XLH进行及早诊断及治疗对患者康复具有极为重要的意义。传统治疗以补充磷酸盐和维生素D类似物为主,随着学者对XLH病理机制研究逐渐深入,分子靶向治疗等新型治疗方式横空出世,通过多学科联合诊断及治疗的方法为患者带去了福音。本文就XLH的临床特征、发病遗传机制、治疗现状及治疗的未来发展趋势进行综述。